Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by SanFrancisco99on Jun 29, 2015 12:05pm
73 Views
Post# 23877162

RE:RE:RE:RE:RE:RE:RE:COULD NOT ZENITH DO THIS??

RE:RE:RE:RE:RE:RE:RE:COULD NOT ZENITH DO THIS??JK:  Glad to hear from you directly.  But your explanation is full of inaccuracies and doesn't acknowledge the fact that you are spreading falsehoods and ignorance here.

Regarding a claim that Zenith is bankrupt, you have zero proof.  it is a pre-market biotech.  Thus, it has no revenue.  Thus, it needs to raise funds from various sources.  Natually, they are not going to divulge any confidential informaiton to do so.  You keep asking for that, and they aren't going to do that - wisely.  Thus, their sources of funds are entirely understandable at this time.

Regarding the patent situation, you keep making silly statements.  Saying "Why does not someone ask RVX or Zenith who held the competing patents, and see if they would enlighten us retail shareolders" is ridiculous!  Your lack of appreciation for the complexities is staggering.  Only lititation in the courts would iron out any such competing patent claims!   The company could not set this forth under any circumstances to retail shareholders in a statement, as NO ONE will know the reletive claims until a court makes a judgement on the issue.  The company has said as much by saying they chose NOT to pursue expensive and time consuming litigating on this matter.

You need to get back within your sphere of knowledge and understanding.  You are clearly outside of that line here.



Bullboard Posts